Pathophysiology of migraine chronification

Research output: Contribution to journalArticle

Abstract

In approximately 3% of migraineurs, migraine evolves into more protracted and severe conditions annually. Meanwhile, approximately 26% of chronic migraine cases regain the episodic nature of migraine headaches in two years. The prevalence of chronic migraine is estimated to be approximately 1%. Although the pathophysiology of migraine chronification is poorly understood, several studies have demonstrated abnormalities in pain processing mechanisms. Of note, the descending pain inhibitory system has been found to be defective in chronic migraine patients. Topiramate appears to ameliorate the disease conditions by correcting such abnormalities in the pain processing mechanisms. Neurogenic inflammation around the dural trigeminal afferents is known to play an important role in the generation of migraine attacks. Botulinum neurotoxins inhibit regulated exocytosis at the nerve terminals by cleaving the SNARE protein, SNAP25. As a result, release of migraine-related neuropeptides, calcitonin gene-related peptide and substance P, is reduced. Moreover, the insertion of transient receptor potential vanilloid subfamily, member 1 (TRPV1) into the plasma membrane is hindered by BoNT-A. We have demonstrated that the inability of TRPV1 to translocate to the plasma membrane results in its proteasome-mediated degradation within the trigeminal ganglion neurons, which may be relevant to the efficacy of BoNT-A against chronic migraine.

Original languageEnglish
Pages (from-to)1220-1222
Number of pages3
JournalClinical Neurology
Volume53
Issue number11
DOIs
Publication statusPublished - 2013

Fingerprint

Migraine Disorders
TRPV Cation Channels
Pain
Cell Membrane
Neurogenic Inflammation
SNARE Proteins
Trigeminal Ganglion
Calcitonin Gene-Related Peptide
Exocytosis
Neurotoxins
Proteasome Endopeptidase Complex
Substance P
Neuropeptides
Neurons

Keywords

  • Central sensitization
  • Chronic migraine
  • Migraine chronification
  • Neurogenic inflammation
  • TRPV1

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Pathophysiology of migraine chronification. / Shibata, Mamoru.

In: Clinical Neurology, Vol. 53, No. 11, 2013, p. 1220-1222.

Research output: Contribution to journalArticle

Shibata, Mamoru. / Pathophysiology of migraine chronification. In: Clinical Neurology. 2013 ; Vol. 53, No. 11. pp. 1220-1222.
@article{ee1225c54ca9436cab9e1f930e6a606a,
title = "Pathophysiology of migraine chronification",
abstract = "In approximately 3{\%} of migraineurs, migraine evolves into more protracted and severe conditions annually. Meanwhile, approximately 26{\%} of chronic migraine cases regain the episodic nature of migraine headaches in two years. The prevalence of chronic migraine is estimated to be approximately 1{\%}. Although the pathophysiology of migraine chronification is poorly understood, several studies have demonstrated abnormalities in pain processing mechanisms. Of note, the descending pain inhibitory system has been found to be defective in chronic migraine patients. Topiramate appears to ameliorate the disease conditions by correcting such abnormalities in the pain processing mechanisms. Neurogenic inflammation around the dural trigeminal afferents is known to play an important role in the generation of migraine attacks. Botulinum neurotoxins inhibit regulated exocytosis at the nerve terminals by cleaving the SNARE protein, SNAP25. As a result, release of migraine-related neuropeptides, calcitonin gene-related peptide and substance P, is reduced. Moreover, the insertion of transient receptor potential vanilloid subfamily, member 1 (TRPV1) into the plasma membrane is hindered by BoNT-A. We have demonstrated that the inability of TRPV1 to translocate to the plasma membrane results in its proteasome-mediated degradation within the trigeminal ganglion neurons, which may be relevant to the efficacy of BoNT-A against chronic migraine.",
keywords = "Central sensitization, Chronic migraine, Migraine chronification, Neurogenic inflammation, TRPV1",
author = "Mamoru Shibata",
year = "2013",
doi = "10.5692/clinicalneurol.53.1220",
language = "English",
volume = "53",
pages = "1220--1222",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Pathophysiology of migraine chronification

AU - Shibata, Mamoru

PY - 2013

Y1 - 2013

N2 - In approximately 3% of migraineurs, migraine evolves into more protracted and severe conditions annually. Meanwhile, approximately 26% of chronic migraine cases regain the episodic nature of migraine headaches in two years. The prevalence of chronic migraine is estimated to be approximately 1%. Although the pathophysiology of migraine chronification is poorly understood, several studies have demonstrated abnormalities in pain processing mechanisms. Of note, the descending pain inhibitory system has been found to be defective in chronic migraine patients. Topiramate appears to ameliorate the disease conditions by correcting such abnormalities in the pain processing mechanisms. Neurogenic inflammation around the dural trigeminal afferents is known to play an important role in the generation of migraine attacks. Botulinum neurotoxins inhibit regulated exocytosis at the nerve terminals by cleaving the SNARE protein, SNAP25. As a result, release of migraine-related neuropeptides, calcitonin gene-related peptide and substance P, is reduced. Moreover, the insertion of transient receptor potential vanilloid subfamily, member 1 (TRPV1) into the plasma membrane is hindered by BoNT-A. We have demonstrated that the inability of TRPV1 to translocate to the plasma membrane results in its proteasome-mediated degradation within the trigeminal ganglion neurons, which may be relevant to the efficacy of BoNT-A against chronic migraine.

AB - In approximately 3% of migraineurs, migraine evolves into more protracted and severe conditions annually. Meanwhile, approximately 26% of chronic migraine cases regain the episodic nature of migraine headaches in two years. The prevalence of chronic migraine is estimated to be approximately 1%. Although the pathophysiology of migraine chronification is poorly understood, several studies have demonstrated abnormalities in pain processing mechanisms. Of note, the descending pain inhibitory system has been found to be defective in chronic migraine patients. Topiramate appears to ameliorate the disease conditions by correcting such abnormalities in the pain processing mechanisms. Neurogenic inflammation around the dural trigeminal afferents is known to play an important role in the generation of migraine attacks. Botulinum neurotoxins inhibit regulated exocytosis at the nerve terminals by cleaving the SNARE protein, SNAP25. As a result, release of migraine-related neuropeptides, calcitonin gene-related peptide and substance P, is reduced. Moreover, the insertion of transient receptor potential vanilloid subfamily, member 1 (TRPV1) into the plasma membrane is hindered by BoNT-A. We have demonstrated that the inability of TRPV1 to translocate to the plasma membrane results in its proteasome-mediated degradation within the trigeminal ganglion neurons, which may be relevant to the efficacy of BoNT-A against chronic migraine.

KW - Central sensitization

KW - Chronic migraine

KW - Migraine chronification

KW - Neurogenic inflammation

KW - TRPV1

UR - http://www.scopus.com/inward/record.url?scp=84891795144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891795144&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.53.1220

DO - 10.5692/clinicalneurol.53.1220

M3 - Article

VL - 53

SP - 1220

EP - 1222

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -